David W. Osborne is CTO at Arcutis Biotherapeutics, Inc. (ARQT). They have made 3 open-market trades across 1 company since 2020, most recently 2023-03-06.
CIK 0001252999
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ARQT | 268,854 | $9.2M |
Shares reported on the most recent Form 4, priced at the 2023-03-08 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ARQT | SELL · 10b5-1 | 2023-03-06 | 2023-03-08 | $15.26 | $11K | -13.4% | -7.4% | -35.5% |
| ARQT | SELL · 10b5-1 | 2023-02-28 | 2023-03-02 | $15.96 | $32K | -27.4% | -29.4% | -52.5% |
| ARQT | SELL | 2022-07-08 | 2022-07-12 | $25.41 | $112K | -7.4% | +6.9% | -18.0% |
| ARQT | SELL · 10b5-1 | 2022-04-21 | 2022-04-21 | $20.42 | $45K | +7.7% | +6.7% | +20.5% |
| ARQT | SELL · 10b5-1 | 2022-03-04 | 2022-03-07 | $16.85 | $14K | +3.1% | +25.1% | +23.7% |
| ARQT | SELL · 10b5-1 | 2022-03-01 | 2022-03-03 | $17.75 | $14K | -6.5% | +24.9% | +18.7% |
| ARQT | SELL · 10b5-1 | 2021-03-01 | 2021-03-03 | $34.57 | $27K | -0.6% | -15.2% | -16.3% |
| ARQT | SELL | 2020-12-14 | 2020-12-16 | $30.00 | $450K | -7.3% | -8.1% | -0.7% |
| ARQT | SELL | 2020-09-29 | 2020-10-01 | $30.00 | $450K | +0.3% | -23.1% | +20.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.